Literature DB >> 23966626

Reduced T-dependent humoral immunity in CD20-deficient mice.

Deyaa El Deen Morsy1, Ratna Sanyal, Anne K Zaiss, Rucha Deo, Dan A Muruve, Julie P Deans.   

Abstract

CD20 is a tetraspanning membrane protein expressed on B lymphocytes. CD20 deficiency in both mice and humans has recently been shown to have deleterious effects on Ab responses to T-independent Ags; however, no effect on T-dependent immunity has been reported. In this study, we used a Cd20⁻/⁻ mouse line to evaluate Ab responses to adeno-associated virus and SRBCs. The neutralizing Ab response to adeno-associated virus was significantly reduced by CD20 deficiency; both primary (IgM) and secondary (IgG1 and IgG2b) responses to SRBC were also reduced in Cd20⁻/⁻ mice, and this was associated with a reduction in the number of germinal center B cells. A successful humoral response requires the integration of intracellular signaling networks that critically rely on calcium mobilization. In this article, we confirm that BCR-mediated calcium mobilization is reduced in Cd20⁻/⁻ murine B cells after BCR stimulation in vitro, and further show that the reduction is due to an effect on calcium influx rather than calcium release from intracellular stores. Calcium-dependent upregulation of CD69 was impaired in CD20-deficient B cells, as was upregulation of CD86. Altogether, this study demonstrates a role for CD20 in B cell activation and T-dependent humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23966626     DOI: 10.4049/jimmunol.1202098

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

2.  Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.

Authors:  A A Vo; S C Jordan
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 3.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

Review 4.  The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Authors:  Per Soelberg Sorensen; Morten Blinkenberg
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

5.  MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.

Authors:  Ratna Sanyal; Maria J Polyak; Jonathan Zuccolo; Mandip Puri; Lili Deng; Luc Roberts; Ania Zuba; Jan Storek; Joanne M Luider; Ellen M Sundberg; Adnan Mansoor; Eva Baigorri; Michael P Chu; Andrew R Belch; Linda M Pilarski; Julie P Deans
Journal:  Immunol Cell Biol       Date:  2017-03-17       Impact factor: 5.126

Review 6.  B- and T-Cell Subset Abnormalities in Monogenic Common Variable Immunodeficiency.

Authors:  Saba Fekrvand; Shaghayegh Khanmohammadi; Hassan Abolhassani; Reza Yazdani
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

7.  CXCL12 Mediates Aberrant Costimulation of B Lymphocytes in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Immunodeficiency.

Authors:  Giuliana Roselli; Elisa Martini; Vassilios Lougaris; Raffaele Badolato; Antonella Viola; Marinos Kallikourdis
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 8.  Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Authors:  Michael J E Marshall; Richard J Stopforth; Mark S Cragg
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

Review 9.  Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.

Authors:  Feras M Ghazawi; Megan Lim; Jan P Dutz; Mark G Kirchhof
Journal:  Int J Dermatol       Date:  2020-07-03       Impact factor: 2.736

10.  Anti-CD20 monoclonal antibodies: reviewing a revolution.

Authors:  J M L Casan; J Wong; M J Northcott; S Opat
Journal:  Hum Vaccin Immunother       Date:  2018-09-06       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.